July 31, 2013

FDA Advisory Committee Recommends Approval of Sanofi’s Nasacort® AQ Nasal Spray for Over-the-Counter Use

Treats Seasonal and Year-round Nasal Allergy Symptoms in Adults and Children

 

FDA Advisory Committee Recommends Approval of Sanofi’s Nasacort® AQ Nasal Spray for Over-the-Counter Use
Treats Seasonal and Year-round Nasal Allergy Symptoms in Adults and Children

Paris, France, July 31, 2013 — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration’s (FDA) Nonprescription Drugs Advisory Committee (NDAC) voted 10 to 6, with 2 abstentions, recommending approval of Nasacort AQ Nasal Spray (triamcinolone acetonide) for over-the-counter use in the U.S.